Abiopharma

New Form 6-K - BELITE BIO, INC Filed: 2025-08-07 AccNo: 0001104659-25-075001 Size: 377 KB

New Form 8-K - Ainos, Inc. Filed: 2025-08-07 AccNo: 0001493152-25-011679 Size: 271 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

STRATA Skin Sciences Moves to Accelerate Medicare and Private Payer Coverage from Expanded CPT Code Expansion, Tripling Addressable Market to 30M+ Patients

Nuwellis to Exit International Operations to Accelerate U.S. Revenue Growth and Strategic Focus

New Form 6-K - InflaRx N.V. Filed: 2025-08-07 AccNo: 0001213900-25-072826 Size: 3 MB

New Form 10-Q - Senti Biosciences, Inc. Filed: 2025-08-07 AccNo: 0001854270-25-000090 Size: 7 MB

New Form 8-K - Rallybio Corp Filed: 2025-08-07 AccNo: 0001739410-25-000108 Size: 241 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form 10-Q - Replimune Group, Inc. Filed: 2025-08-07 AccNo: 0001737953-25-000013 Size: 7 MB

New Form 10-Q - RAPT Therapeutics, Inc. Filed: 2025-08-07 AccNo: 0000950170-25-104598 Size: 7 MB

New Form 10-Q - Barinthus Biotherapeutics plc. Filed: 2025-08-07 AccNo: 0001828185-25-000059 Size: 5 MB

New Form 8-K - Senti Biosciences, Inc. Filed: 2025-08-07 AccNo: 0001854270-25-000088 Size: 233 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form 8-K - ESTABLISHMENT LABS HOLDINGS INC. Filed: 2025-08-07 AccNo: 0001688757-25-000054 Size: 351 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form 10-Q - Edgewise Therapeutics, Inc. Filed: 2025-08-07 AccNo: 0001558370-25-010655 Size: 5 MB

New Form 8-K - Replimune Group, Inc. Filed: 2025-08-07 AccNo: 0001104659-25-074989 Size: 242 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form 8-K - RAPT Therapeutics, Inc. Filed: 2025-08-07 AccNo: 0000950170-25-104596 Size: 365 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits